Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program | BHC Stock News

Author's Avatar
Apr 10, 2025
Article's Main Image
  • Bausch Health (BHC, Financial) and Ortho Dermatologics launch 2025 ASPIRE HIGHER Scholarship Program.
  • Six scholarships worth up to $10,000 each are available for students with dermatologic conditions.
  • Application deadline is June 11, 2025, with awards announced in July 2025.

Bausch Health Companies Inc. (BHC) and its dermatology division, Ortho Dermatologics, have announced the opening of the 2025 ASPIRE HIGHER Scholarship Program. This initiative is dedicated to supporting students affected by dermatologic conditions through the provision of six scholarships, each valued at up to $10,000. This program aims to alleviate financial barriers for students pursuing higher education during the 2025-2026 academic year.

The scholarship program offers three Undergraduate Scholar Awards for students entering undergraduate or vocational/technical programs and three Graduate Scholar Awards for those undertaking graduate-level education. Interested students are required to complete an online application form, submit an essay that discusses their personal experiences with a diagnosed dermatologic condition and their healthcare provider's impact, and provide two letters of reference.

Applications for these scholarships are being accepted now through June 11, 2025. Scholarship recipients will be announced in July 2025, providing timely support as they continue their educational pursuits. For more information on eligibility and application details, applicants are encouraged to visit the official website at www.aspirehigherscholarships.com.

Bausch Health (BHC, Financial) is a global leader in pharmaceuticals, with a particular focus on dermatology through its Ortho Dermatologics division. This division is renowned for its commitment to improving treatment options for various skin conditions such as psoriasis, acne, and dermatitis.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.